[go: up one dir, main page]

MX2020010259A - Preparacion farmaceutica. - Google Patents

Preparacion farmaceutica.

Info

Publication number
MX2020010259A
MX2020010259A MX2020010259A MX2020010259A MX2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A MX 2020010259 A MX2020010259 A MX 2020010259A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
provides
present
preparation
rosuvastatin
Prior art date
Application number
MX2020010259A
Other languages
English (en)
Inventor
Sang Yeop Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67055715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020010259(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MX2020010259A publication Critical patent/MX2020010259A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una preparación que contiene fimasartán, amlodipino y rosuvastatina como principios activos. La presente invención proporciona una preparación que tiene una excelente velocidad de disolución para cada principio activo y una alta estabilidad, permitiendo de este modo mejorar notablemente la conveniencia de la administración.
MX2020010259A 2018-04-30 2019-04-29 Preparacion farmaceutica. MX2020010259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180050277A KR101992400B1 (ko) 2018-04-30 2018-04-30 약학적 제제
PCT/KR2019/005151 WO2019212214A1 (ko) 2018-04-30 2019-04-29 약학적 제제

Publications (1)

Publication Number Publication Date
MX2020010259A true MX2020010259A (es) 2020-10-22

Family

ID=67055715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010259A MX2020010259A (es) 2018-04-30 2019-04-29 Preparacion farmaceutica.

Country Status (10)

Country Link
KR (1) KR101992400B1 (es)
CN (1) CN112040933A (es)
MX (1) MX2020010259A (es)
MY (1) MY203254A (es)
PH (1) PH12020551547A1 (es)
RU (1) RU2756452C1 (es)
SG (1) SG11202009187YA (es)
TW (1) TWI697339B (es)
WO (1) WO2019212214A1 (es)
ZA (1) ZA202006346B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102595702B1 (ko) * 2021-06-09 2023-10-30 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336922A (zh) * 2008-08-08 2009-01-07 青岛黄海制药有限责任公司 一种瑞舒伐他汀氨氯地平组合物
SMT201800495T1 (it) * 2009-11-13 2018-11-09 Astrazeneca Ab Formulazioni di compresse a doppio strato
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물
SG10201502582PA (en) * 2012-03-30 2015-05-28 Dae Woong Pharma Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN103156842B (zh) * 2013-03-08 2014-05-28 南开大学 牛蒡子苷元在制备抗心律失常药物中的用途
US9592233B2 (en) * 2013-03-14 2017-03-14 Boryung Pharmaceutical Co., Ltd. Pharmaceutical combination drug
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
PT3320903T (pt) * 2015-07-08 2021-08-19 Hk Inno N Corp Composição farmacêutica contendo amlodipina, valsartan e rosuvastatina
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염

Also Published As

Publication number Publication date
KR101992400B1 (ko) 2019-06-24
TWI697339B (zh) 2020-07-01
MY203254A (en) 2024-06-20
PH12020551547A1 (en) 2021-06-07
RU2756452C1 (ru) 2021-09-30
TW201946916A (zh) 2019-12-16
WO2019212214A1 (ko) 2019-11-07
SG11202009187YA (en) 2020-10-29
ZA202006346B (en) 2022-01-26
CN112040933A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MX388786B (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
ECSP20023535A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
MX2020010259A (es) Preparacion farmaceutica.
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
CO2017011297A2 (es) Una composición farmacéutica antiviral de uso tópico
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
MX392546B (es) Composición parenteral de casiopeína y usos de la misma.
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
ECSP19040732A (es) Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina
IN2013MU02110A (es)